1093066-82-0

Basic information

• Product Name: tert-Butyl 4-(azetidin-1-yl)piperidine-1-carboxylate
• Synonyms: 4-Azetidin-1-yl-piperidine-1-carboxylic acid tert-butyl ester;tert-Butyl 4-(azetidin-1-yl)piperidine-1-carboxylate
• CAS NO: 1093066-82-0
• Molecular Formula: C13H24N2O2
• Molecular Weight: 240
• Mol File: 1093066-82-0.mol

Chemical Properties

• Boiling Point: 315.0±35.0 °C(Predicted)
• Appearance: /
• Density: 1.090±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 10.18±0.20(Predicted)
• CAS DataBase Reference: tert-Butyl 4-(azetidin-1-yl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 4-(azetidin-1-yl)piperidine-1-carboxylate(1093066-82-0)
• EPA Substance Registry System: tert-Butyl 4-(azetidin-1-yl)piperidine-1-carboxylate(1093066-82-0)

Safety Data

• Hazardous Substances Data: 1093066-82-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tert-Butyl 4-(azetidin-1-yl)piperidine-1-carboxylate is used as a reagent in organic synthesis for the production of pharmaceuticals. Its unique structure and strong nucleophilic activity make it an important component in the synthesis of various nitrogen-containing compounds, contributing to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, tert-Butyl 4-(azetidin-1-yl)piperidine-1-carboxylate is utilized as a reagent in the synthesis of agrochemicals. Its properties allow for the creation of nitrogen-containing compounds that can be used in the development of pesticides, herbicides, and other agricultural chemicals, enhancing crop protection and yield.
Used in Organic Synthesis:
Tert-Butyl 4-(azetidin-1-yl)piperidine-1-carboxylate is employed as a key building block in organic synthesis. Its strong nucleophilic activity and stability make it suitable for a wide range of chemical reactions, facilitating the synthesis of complex organic molecules for various applications in the field of organic chemistry.

Upstream product

• 503-29-7 azetidine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 65546-09-0 azetidine hydrochloride 

Relevant articles and documents

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

Compounds of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), and methods of use as lnterleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS

Thienopyrimidines of formula (I) wherein W and R1 to R4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS

This invention provides a compound which is a purine of formula (Ia) or (Ib): and the pharmaceutically acceptable salts thereof that are inhibitors of PI3K and a selective for the p110δ isoform, which is a class Ia PI3 kinase, over other class Ia PI3 kinases and over class Ib kinases. The compounds may be used to treat diseases and disorders arisi from abnormal cell growth, function or behaviour associated with PI3 kinase such as cance immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

PHARMACEUTICAL COMPOUNDS

Furanopyrimidines of formula (I): wherein W represents a furan ring; R1 and R2 form, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is selected from: (a) a 4- to 7-membered saturated N-containing heterocyclic ring which includes 0 or 1 additional heteroatoms selected from N, S and O, the ring being fused to a second ring selected from a 4- to 7-membered saturated N-containing heterocyclic ring as defined above, a 5- to 12-membered unsaturated heterocyclic ring, a 5- to 7-membered saturated O-containing heterocyclic ring, a 3- to 12- membered saturated carbocyclic ring and an unsaturated 5- to 12- membered carbocyclic ring to form a heteropolycyclic ring system, the heteropolycyclic ring system being unsubstituted or substituted; (b) a 4- to 7-membered saturated N-containing heterocyclic ring which includes 0 or 1 additional heteroatoms selected from N, S and O and which further comprises, linking two constituent atoms of the ring, a bridgehead group selected from -(CR'2)n- and -(CR'2)r-O-(CR'2)s- wherein each R' is independently H or C1 - C6 alkyl, n is 1, 2 or 3, r is 0 or 1 and s is 0 or 1, the remaining ring positions being unsubstituted or substituted; and (c) a group of formula (IIb): wherein ring B is a 4- to 7-membered saturated N-containing heterocyclic ring which includes 0 or 1 additional heteroatoms selected from N, S and O and ring B' is a 3- to 12- membered saturated carbocyclic ring, a 5- to 7- membered saturated O-containing heterocyclic ring or a 4- to 7-membered saturated N-containing heterocyclic ring as defined above, each of B and B' being unsubstituted or substituted; m is 0, 1 or 2; R3 is H or C1-C6 alkyl; R4 is an indole group which is unsubstituted or substituted; and Ra is selected from R, halo, CN, C(O)NR2, halo(C1-C6)alkyl, SO2R, SO2NR2, NRSO2R, NRC(O)R, NRC(O)OR and NRC(O)NR2 wherein each R is independently H or C1-C6 alkyl; and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE

Thiazolopyrimidines of formula (I): wherein W represents a thiazole ring; R1 and R2 form, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is a ring system; m is 0, 1 or 2; Rsup